MESO
Mesoblast Limited
NASDAQ · Healthcare · Biotechnology · AU
$17.32
+1.05%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 120.8M | 120.8M | 17.2M | 5.9M | 7.5M |
| Cost of Revenue | 19.2M | 19.2M | 5.1M | 41.1M | 54.9M |
| Gross Profit | 96.2M | 101.6M | 12.1M | (35.2M) | (47.4M) |
| Operating Expenses | |||||
| R&D Expense | 97.5M | 97.9M | 34.8M | 25.4M | 27.2M |
| SG&A Expense | 57.3M | 55.1M | 39.3M | 23.6M | 53.1M |
| General & Admin Expense | — | — | 23.2M | 11.8M | 25.4M |
| Selling & Marketing Expense | — | — | 16.1M | 11.8M | 27.7M |
| Other Expenses | — | — | 395.0K | — | — |
| Total Operating Expenses | 154.9M | 153.1M | 74.5M | 49.0M | 76.8M |
| Cost and Expenses | 172.3M | 172.3M | 79.6M | 90.0M | 76.8M |
| Operating Income (EBIT) | (118.1M) | (51.5M) | (62.4M) | (84.1M) | (69.3M) |
| Non-Operating | |||||
| Interest Income | — | 3.9M | 3.6M | 1.8M | 831.0K |
| Interest Expense | 11.3M | 23.9M | 22.9M | 20.7M | 19.4M |
| Net Interest Income | (16.0M) | (20.0M) | (19.4M) | (18.8M) | (18.6M) |
| Other Non-Op Income/Expense | 49.3M | (5.6M) | (39.4M) | (4.0M) | (12.8M) |
| Non-Operating Income (excl Interest) | (66.9M) | — | 17.6M | 26.2M | (6.6M) |
| EBT (Pre-Tax Income) | (56.9M) | (57.1M) | (101.8M) | (88.1M) | (82.1M) |
| Income Tax Expense | 613.0K | 615.7K | 330.0K | (191.0K) | (212.0K) |
| Bottom Line | |||||
| Net Income | (57.5M) | (57.8M) | (102.1M) | (88.0M) | (81.9M) |
| Earnings from Cont. Ops | (57.5M) | (57.8M) | (102.1M) | (88.0M) | (81.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (57.5M) | (57.8M) | (102.1M) | (88.0M) | (81.9M) |
| Per Share | |||||
| Basic EPS | ($0.43) | ($0.45) | ($0.84) | ($0.89) | ($0.98) |
| Diluted EPS | ($0.43) | ($0.45) | ($0.84) | ($0.89) | ($0.98) |
| Revenue Per Share | $0.93 | $0.93 | $0.14 | $0.06 | $0.09 |
| Shares | |||||
| Basic Shares Outstanding | 129.8M | 129.5M | 120.8M | 98.7M | 83.8M |
| Diluted Shares Outstanding | 129.8M | 129.5M | 120.8M | 98.7M | 83.9M |
| Profitability Metrics | |||||
| EBITDA | (45.0M) | (42.9M) | (73.7M) | (56.1M) | (58.5M) |
| D&A | 6.2M | 8.6M | 6.4M | 1.9M | 4.1M |
| EBIT | (51.3M) | (51.5M) | (80.1M) | (58.0M) | (62.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026